Exome sequencing identifies a novel mutation in the MYH6 gene in a family with early-onset sinus node dysfunction, ventricular arrhythmias, and cardiac arrest  by Lam, Lien et al.
Exome sequencing identiﬁes a novel mutation in the
MYH6 gene in a family with early-onset sinus node
dysfunction, ventricular arrhythmias, and cardiac arrest
Lien Lam, BSc, PhD,* Jodie Ingles, BBiomed Sci, PhD, MPH,*† Christian Turner, MBBS,‡
Michael Kilborn, MBBS, PhD,*†§ Richard D. Bagnall, BSc, PhD,*† Christopher Semsarian, MBBS, PhD, MPH, FHRS*†§
From the *Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Sydney, New South Wales, Australia, †Sydney
Medical School, University of Sydney, Sydney, New South Wales, Australia, ‡The Heart Centre for Children, The Children’s
Hospital at Westmead, Sydney, New South Wales, Australia, and §Department of Cardiology, Royal Prince Alfred Hospital,
Sydney, New South Wales, Australia.Introduction
Cardiac arrhythmias leading to sudden death can be the
ﬁrst manifestation of an underlying genetic heart disease
such as an inherited cardiomyopathy or primary arrhythmo-
genic disorder. In a number of cases, a clinical diagnosis
cannot be established despite comprehensive clinical
review. Genetic investigations can aid clinical diagnosis
and uncover new disease loci and mechanisms related to
cardiac arrhythmias and sudden death.
Sudden cardiac death can be the ﬁrst manifestation of an
underlying heart condition in otherwise healthy individu-
als. The predominant cause of sudden cardiac death in
those older than 35 years is coronary artery disease. In
those younger than 35 years, sudden cardiac death can be
caused by a genetic heart disorder, which can be structural
(eg, hypertrophic and dilated cardiomyopathies) or
arrhythmogenic (eg, long QT syndrome [LQTS], catecho-
laminergic polymorphic ventricular tachycardia [CPVT],
and Brugada syndrome).1 However, there remains a group
of individuals in whom the cause of sudden cardiac death is
unknown.2KEYWORDS Arrhythmias; Genetics; Exome sequencing; Cardiac arrest; Sinus
node dysfunction
ABBREVIATIONS CMR ¼ cardiac magnetic resonance; CPVT ¼
catecholaminergic polymorphic ventricular tachycardia; ECG ¼
electrocardiogram; ICD ¼ implantable cardioverter-defibrillator; LQTS
¼ long QT syndrome; MYH6 ¼ myosin heavy chain 6 gene; PPM ¼
permanent pacemaker; SNV ¼ single nucleotide variant
(Heart Rhythm Case Reports 2015;1:141–145)
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Remarkable advances over the past 2 decades have helped
discover genetic contributions to cardiac arrhythmias and
sudden death. Defects in different cardiac ion channel genes
have been linked to speciﬁc forms of inherited arrhythmo-
genic disorders.3 In cases where idiopathic ventricular
ﬁbrillation is the ﬁrst sign of cardiac dysfunction and no
cause is demonstrable on clinical evaluation, genetic testing
has identiﬁed the underlying cardiac disease.4 Furthermore, a
positive genetic result allows predictive testing of asympto-
matic family members at risk of premature death. Never-
theless, some cases have no identiﬁable mutation in known
disease-causing genes and therefore highlight the necessity
to discover new susceptibility genes for inherited arrhythmo-
genic disorders.
Advances in next-generation sequencing platforms and
targeted DNA capture strategies allow vastly greater capacity
to sequence many thousands of genes at once, offering the
ability to identify new genetic loci and mechanisms for
cardiac electrical abnormalities.5 Herein, we describe the
clinical and genetic investigation of a 3-generation family
with a spectrum of cardiac arrhythmia phenotypes among 4
ﬁrst-degree relatives, including sinus node dysfunction,
ventricular ﬁbrillation, and sudden cardiac arrest.Methods
Clinical assessment
Clinical evaluation of family members was performed at the
Genetic Heart Diseases Clinic, Royal Prince Alfred Hospital,
Sydney, and the Heart Centre for Children, The Children’s
Hospital at Westmead, Sydney, Australia. Clinical assess-
ment included detailed family history, physical examination,
12-lead electrocardiogram (ECG), transthoracic echocar-
diography, 24-hour Holter monitoring, and cardiac magnetic
resonance (CMR) imaging. All family members provided
written informed consent, including parental consent for
children.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.01.022
KEY TEACHING POINTS
 Phenotype heterogeneity is a hallmark of many
inherited arrhythmia syndromes, spanning sinus
node disease to ventricular arrhythmias in the same
family.
 Exome sequencing enables genetic analysis of
hundreds of cardiac genes at the same time and is a
useful approach in families with inherited
arrhythmia, where conventional genetic testing in
known genes does not identify the cause of sudden
cardiac death.
 Determining pathogenicity of the identiﬁed DNA
variants involves many aspects, including
demonstration of cosegregation in clinically
affected family members and supporting
functional data.
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Commercial genetic testing of the index case for mutations
in 6 common familial LQTS genes (KCNQ1, KCNH2,
KCNE1, KCNE2, KCNJ2, and SCN5A) and the CPVT gene
(RYR2) was previously performed, and no pathogenic
mutations were identiﬁed in the index case. Therefore,
whole exome sequencing and analysis of the proband was
performed as described previously.5 In brief, the DNA
sequencing library was prepared and enriched for the
Illumina TruSeq Exome and paired-end sequenced on an
Illumina HiSeq2000 system (Macrogen Facility, Seoul,
Korea). Single nucleotide variants (SNVs) and insertions,
deletions (InDels) causing a nonsynonymous, nonsense,
altered splice site or a frameshift change and with a minor
allele frequency (MAF) of o1% in the 1000 Genomes
Project (http://www.1000genomes.org/) and 6500 control
exomes from the NHLBI Exome Sequencing Project














I:1 M 63 57 10 9 46 21
I:2 F 64 58 10 10 46 23
II:1 M 29 24 9 9 58 24
II:2 F 32 31 7 7 41 12
II:3 F 27 21 8 9 44 NA
III:1 F 7 7 5 4 42 NA
III:2 M 5 NA NA NA NA NA
III:3 F 1 1 NA NA 28 NA
þ/ ¼ mutation positive; / ¼ mutation negative; ECG ¼ electrocardiogra
deﬁbrillator; IVF ¼ idiopathic ventricular ﬁbrillation; LA ¼ left atrium; LVEDD ¼ le
thickness; M ¼ male; N ¼ no; NA ¼ not available; PPM ¼ permanent pacemaker;
resuscitated cardiac arrest; VEB ¼ ventricular ectopic beat; Y ¼ yes.validation and cosegregation in family members were
determined by Sanger sequencing.
All studies were carried out with approval of and in strict
accordance with the Sydney Local Health District Ethics
Review Committee.
Results
Clinical feature of a family
We present a 3-generation Australian family with marked
clinical heterogeneity. The clinical characteristics are sum-
marized in Table 1, and the pedigree is illustrated in
Figure 1A. The male index case (II:1) experienced an out-
of-hospital sudden cardiac arrest at the age of 24 years. His
initial cardiac rhythm was recorded as ventricular ﬁbrillation.
His initial postarrest ECG showed sinus rhythm with right
bundle branch block and monomorphic ventricular ectopy.
Echocardiogram and CMR imaging showed a mildly dilated
left ventricle and mildly reduced ejection fraction, which
subsequently improved. An electrophysiological study
showed no inducible ventricular tachycardia. An implantable
cardioverter-deﬁbrillator (ICD) was subsequently implanted
for secondary prevention, and he remained stable and free
from appropriate device therapies after 4 years of follow-up.
Clinical screening of ﬁrst-degree relatives was initiated.
The father (I:1) and mother (I:2) of the index case had normal
ECGs and exercise stress tests. His sister (II:3) had a clinical
history of symptomatic palpitations and normal ECG,
echocardiogram, CMR imaging, and 24-hour Holter
monitoring.
All 3 children of the index case have been symptomatic.
His eldest daughter (III:1) has sinus node dysfunction and
has experienced episodes of syncope since the age of 9
months. A loop recorder documented junctional bradycardia
with periods of asystole, with an episode of cardiac standstill
as long as 13 seconds (Figure 1B, upper panel). She had a
normal adrenaline provocation test, a normal corrected QT
interval on a resting ECG, and a normal echocardiogram. She
underwent permanent pacemaker (PPM) insertion at the agerea
2)
ECG/Holter
monitor PPM ICD Genotype Diagnosis
Normal N N / Normal
Normal N N þ/ Normal
Abnormal; RBBB;
VEB
N Y þ/ IVF (RCA)
Normal N N / Normal
Normal N N / Normal
13 s of sinus
arrest
Y Y þ/ Sinus node
dysfunction
11 s of sinus
arrest
Y Y þ/ Sinus node
dysfunction
Partial RBBB Y Y þ/ Sinus node
dysfunction
m; ECHO ¼ echocardiography; F ¼ female; ICD ¼ implantable cardioverter-
ft ventricular end-diastolic diameter; LVmax ¼ maximum left ventricular wall
PW ¼ posterior wall thickness; RBBB ¼ right bundle branch block; RCA ¼
Figure 1 Family pedigree, electrical abnormities, and MYH6 mutation. A: The 3-generation pedigree shows affected (ﬁlled) and unaffected (unﬁlled)
individuals. Arrow indicate the index case (II:1). Three affected individuals (III:1, III:2, and III:3) and 1 unaffected individual (I:2) share theMYH6 variant.þ¼
presence of a mutant allele;¼ absence of a mutant allele. B: Sinus pause and arrest traces in III:1 (upper panel) and III:2 (lower panel). Arrows indicate periods
of sinus pause/arrest. C: DNA sequence chromatogram of all family members.
143Lam et al MYH6 Gene in Cardiac Arrhythmiasof 3 years and has had no further events to date. Her PPM
device was upgraded to an ICD at the age of 7 years.
The son (III:2) of the index case has also experienced
episodes of syncope since the age of 12 months. Holter
monitoring recorded an episode that correlated to 11 seconds
of asystole with no ventricular escape (Figure 1B, lower
panel). His ECG showed normal sinus rhythm with normal
QRS axis and intervals. He was implanted with a PPM and
has since continued to have episodes of brief unconscious-
ness, though less pronounced than previous episodes. His
PPM device was upgraded to an ICD at the age of 5 years at
the request of the parents. The youngest daughter (III:3) had
several reported episodes of brief unconsciousness and
unresponsiveness starting at the age of 3 months, with each
episode lasting 5–10 seconds. Her ECG showed normalsinus rhythm with normal QRS axis and intervals. She was
implanted with a PPM at the age of 11 months because of
these recurrent syncopal events, the positive family history,
and the request from the parents. No further episodes have
been recorded to date.Genetic analysis and whole exome sequencing
The index case underwent whole exome sequencing after
commercial genetic testing of 6 LQTS genes (KCNQ1,
KCNH2, KCNE1, KCNE2, KCNJ2, and SCN5A), and the
CPVT gene (RYR2) failed to detect a pathogenic mutation.
Targeted exome capture identiﬁed 208 heterozygous non-
synonymous, nonsense, or altered splice site SNVs after the
aforementioned ﬁltering steps. To identify a potentially
Heart Rhythm Case Reports, Vol 1, No 3, May 2015144causative variant, a Genomic Evolutionary Rate Proﬁling
(GERP) score of Z2, which is the general threshold to
indicate evolutionary constrained nucleotides,6 was applied
to missense variants to retain 149 SNVs (Online
Supplemental Table S1). In addition, 15 rare InDels occur-
ring in coding regions, or causing frameshifts or affecting the
canonical splice site sequences, were detected (Online
Supplemental Table S2). Variants in ion channel genes or
genes associated with cardiac disease were selected for
cosegregation analysis in the family (highlighted in Online
Supplemental Table S1). Analysis revealed a rare hetero-
zygous variant in the cardiac muscle alpha-myosin heavy
chain 6 gene MYH6 (NM_002471.3: c.1960C4T; p.
Arg654Trp). This variant has been identiﬁed in 1 of
61,425 exomes (MAF ¼ 0.000008) of the Exome Aggrega-
tion Consortium data (http://exac.broadinstitute.org) and is
absent from the 1000 Genomes Project and our internal
exomes from 166 unrelated individuals with diverse cardiac
pathologies. Genotyping family members conﬁrmed cose-
gregation of theMYH6 Arg654Trp variant with disease in all
symptomatic individuals (III:1, III:2, and III:3; Figure 1C).
The variant was present in 1 clinically unaffected female (I:2;
Figure 1C). The father (I:1) and sister (II:3) of the index case
do not carry the variant.Discussion
We present a 3-generation Australian family with both
severe and diverse cardiac arrhythmia manifestations of
disease in which a heterozygous mutation in the MYH6 gene
(Arg654Trp) was identiﬁed by whole exome sequencing and
demonstrated to cosegregate with all affected family mem-
bers. The diverse clinical features observed in this family
include early-onset sinus node dysfunction and a resuscitated
cardiac arrest due to ventricular ﬁbrillation, reﬂecting the
pleiotropic nature of MYH6 mutations. In this study, we
provide further support to directly link a mutation in MYH6
to heritable cardiac conduction abnormalities using segrega-
tion analysis.
To date, there has only been 1 report establishing the
importance of MYH6 and the development of cardiac
arrhythmias.7 Holm et al7 performed a genome-wide
association study and whole genome sequencing in Ice-
landic individuals and observed a strong association
between a rare missense variant c.2161C4T (p.
Arg721Trp) in MYH6 and sick sinus syndrome cases. In
addition, in combination with other common MYH6 var-
iants, the c.2161C4T variant associates with decreased
heart rate and prolongation of the PR interval in individuals
who have not been diagnosed with sick sinus syndrome,
indicating that variants in this sarcomere gene are directly
linked to cardiac conduction in humans. The missense
variant we identiﬁed at position c.1960C4T in MYH6
occurs in exon 16 and results in the Arg654Trp substitution
of a highly conserved residue in the myosin globular head.
The myosin head functions as the motor domain and is
composed of actin-binding sites, the ATP-binding pocket,and the converter domain, which are all linked by ﬂexible
single-stranded joints and critical in conformational
changes during muscle contraction.8 Relatively few muta-
tions have been identiﬁed in the MYH6 gene, with those
occurring in the myosin motor domain reported to cause a
number of cardiac outcomes, including dilated9 and hyper-
trophic cardiomyopathies, as well as different forms of
congenital heart defects.10
The clinical features observed in our family are striking.
Although the MYH6 Arg654Trp mutation cosegregated with
disease in the family, we observed incomplete penetrance
and variable expressivity. The ﬁrst manifestation of disease
was a resuscitated cardiac arrest due to ventricular ﬁbrillation
in the index case, while his 3 symptomatic children presented
with sinus node dysfunction all within the ﬁrst year of life.
The presence of both ventricular arrhythmias and sinus node
dysfunction in the same family is an unusual clinical ﬁnding.
Interestingly, a mutation of the residue homologous toMYH6
Arg654Trp in the closely related cardiac myosin isoform
MYH7 (NC_000014.8; p.Arg652Gly) results in hypertrophic
cardiomyopathy.11 While there is currently no clear evidence
of cardiomyopathy in our family, we cannot exclude the
possibility that affected individuals will develop a structural
anomaly in the future.
The MYH6 Arg654Trp mutation is predicted to be
deleterious by software tools PolyPhen-2, SIFT, and Muta-
tionTaster. However, the exact mechanisms involved in the
cardiac conduction abnormalities that we observe in this
family remain to be determined. The expression of MYH6 is
primarily limited to atrial tissues and is associated with faster
rates of contraction.12 Cardiac functional studies in animal
models with reduced MYH6 expression revealed defects in
cardiac contraction, and loss of myh6 in zebraﬁsh caused
aberrant atrial contractility and triggered changes in ven-
tricular morphology and function.13 Thus,MYH6 expression
strongly affects contractile properties of both the atria and
ventricles during development and disease pathology. Fur-
thermore, recent investigation of the cardiac-speciﬁc micro-
RNA, miR-208a, encoded within an intron of MYH6 has
shown evidence of its importance as a modulator of electrical
signals in the heart.14 Overall, the current available data
suggest that MYH6 anomalies can cause cardiac conduction
abnormalities. Given the limited pedigree size and enigmatic
disease characteristics in this family, the role of MYH6
variants in the electrical system of the heart warrants further
functional analyses.Conclusion
We have identiﬁed the MYH6 Arg654Trp variant as a causative
mutation in a familywith dominantly inherited cardiac conduction
disorders. Marked cardiac heterogeneity is observed, including
arrhythmogenic abnormalities resulting in a sudden cardiac arrest
event and symptoms of sinus node dysfunction. The effect of this
mutation highlights the pivotal role ofMYH6 in the maintenance
of normal cardiac conduction and may provide insight into new
mechanisms and pathways involved in disease pathogenesis.
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